Quotables
"That the automobile has practically reached the limit of its development is suggested by the fact that during the past year no improvements of a radical nature have been introduced."
Scientific American ; Jan. 2 edition, 1909
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7875620 | Methods of treating microbial infections The present invention provides methods of treating microbacterial infections comprising administering to a subject in need thereof, a composition comprising a compound of formula I: wherein: | 01/25/2011 |
| 7312223 | Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for preparing the same. ... | 12/25/2007 |
| 7268141 | Xanthine phosphodiesterase V inhibitors A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: | 09/11/2007 |
| 7247639 | A1 adenosine receptor antagonists The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceut... | 07/24/2007 |
| 6774130 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intrace... | 08/10/2004 |
| 6734187 | Purine derivatives and medicaments comprising the same as active ingredient Purine derivatives represented by the following formula and salts thereof: wherein R1 represents a C1-C4 alkyl group or difluoromethyl group; R2 represents tetrahydrofuranyl gr... | 05/11/2004 |
| 6642231 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells a... | 11/04/2003 |
| 6025362 | Uses of xanthine compounds Xanthine compounds are utilized to accelerate anesthetic recovery from the effects of certain compounds as propofol, etomidate, barbiturates, opioids, isoflurane, enflurane, halothane, desflurane, sevoflurane and/or nitrous oxide. In a preferred embodimen... | 02/15/2000 |
| 5872124 | Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite The process of treating a disease of the central nervous system with an agent from one or more of the following three classes of agents: (1) nitric oxide scavengers, (2) peroxynitrite scavengers, and (3) agents that either interfere with the synthesis of ... | 02/16/1999 |
| 5785993 | Reduction of adhesions using controlled delivery of active oxygen inhibitors SOD and other active oxygen inhibitors are directly applied in combination with a barrier material at local sites of tissue injury to prevent or decrease formation of adhesions and undesirable proliferation of cells. Preferred barrier materials are polyme... | 07/28/1998 |
| 5753635 | Purine derivatives and their use as anti-coagulants This invention is directed to purine derivatives of the following formulae: ##STR1## wherein Z1 is --O--, --N(R10)-- or --CH2 O--; Z2 is --O--, --N(R10)-- or --OCH2 --; R1 and R4... | 05/19/1998 |
| 5470858 | Derivatives of (hetero)aromatic ethers and thioethers having antihyperlipidemic activity, process for their preparation and pharmaceutical compositions containing them A compound represented by the following formula I: (HET)Ar--X--CH2 --Y--CH2 --O--R (I) wherein: (HET)Ar represents a bicyclic hetero aryl nucleus which is unsubstituted or is substituted; X represents --S--; Y represents --CO-... | 11/28/1995 |
| 4883801 | Xanthine derivative pest control agents The use of xanthine derivatives having the general formula: ##STR1## as pesticidal and pestistatic agents is disclosed, as well as pesticidal and pestistatic compositions containing same.... | 11/28/1989 |
| 4871742 | Process and pharmaceutical compositions for the treatment of glaucoma The invention relates to a process for the treatment of glaucoma comprising administering to a human in need thereof an effective amount of a compound selected from the inhibitors of xanthine-oxidase.... | 10/03/1989 |
| 4853373 | Therapeutic treatment for arthritic condition Hypoxanthine administered intradermally at a dosage range of 2×10-8 to 1×10-5 grams to a mammalian subject for the purpose of treating rheumatoid arthritis and osteoarthritis.... | 08/01/1989 |
| 4107306 | Process for treating proliferative skin disease A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc. comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one ... | 08/15/1978 |
